Postbiotics are preparations of inanimate microorganisms and/or their components that confer a health benefit on the host, as defined by the International Scientific Association for Probiotics and Prebiotics (ISAPP) in its 2021 consensus statement.[1] Unlike probiotics, which require live microorganisms to survive manufacturing, storage, and gastrointestinal transit, postbiotics are intentionally inactivated microbial preparations that deliver biological effects without bacterial viability. Common inactivation methods include heat treatment (pasteurization, tyndallization), ultraviolet irradiation, and high-pressure processing. The ISAPP definition requires that the progenitor microorganism be precisely characterized at genus, species, and strain level, and that a health benefit be demonstrated in the target host.[1] For supplement formulators, postbiotics offer a distinct category of microbiome-derived ingredients with superior shelf stability, broader dosage form compatibility, and a favorable safety profile compared to live probiotic preparations. Commercially available postbiotic ingredients include EpiCor (Cargill), IMMUSE LC-Plasma (Kyowa Hakko), Plenibiotic (Kerry Group), LAC-Shield (Morinaga), and pasteurized Akkermansia muciniphila (A-Mansia Biotech), each supported by clinical evidence across immune, metabolic, and gut health applications.
Table of Contents
- How Postbiotics Differ from Probiotics, Prebiotics, and Synbiotics
- Human Clinical Evidence for Postbiotic Ingredients
- Formulation Advantages: Stability, Shelf Life, and Dosage Form Compatibility
- Safety Profile and Advantages Over Live Probiotics
- Regulatory Status by Region
- Supplier Landscape: Branded Postbiotic Ingredients
- Quality, Analytical Methods, and Standardization
- FAQs
- Key Takeaways
- Sources
How Postbiotics Differ from Probiotics, Prebiotics, and Synbiotics
Postbiotics occupy a distinct position within the broader “biotics” category used in dietary supplement formulation. Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. Prebiotics are substrates (typically dietary fibers such as inulin and fructooligosaccharides) selectively utilized by host microorganisms to confer a health benefit. Synbiotics combine a probiotic and a prebiotic in a single formulation.[1]
Postbiotics differ fundamentally because they do not require microbial viability. The biological effects of postbiotic preparations derive from retained cellular structures (cell wall fragments, peptidoglycans, surface proteins), metabolites produced during fermentation, or the combination of both. This distinction has practical consequences for the entire supply chain: postbiotic ingredients do not require cold-chain logistics, are not subject to colony-forming unit (CFU) decay during storage, and are compatible with processing conditions that would destroy live probiotic strains.[2]
The ISAPP definition also establishes clear boundaries for the term.[1,3] Purified metabolites alone (such as isolated butyric acid or lactic acid without cellular biomass), vaccines, substantially purified single components, filtrates lacking cell components, and products from undefined microbial cultures do not qualify as postbiotics. A product marketed as a “postbiotic” must be traceable to a defined progenitor strain characterized at genus, species, and strain level, and supported by clinical evidence of a health benefit in humans.
Human Clinical Evidence for Postbiotic Ingredients
Several postbiotic preparations have been evaluated in randomized, controlled human trials across immune, metabolic, and gastrointestinal applications. The evidence base, while growing, varies substantially by ingredient.
Pasteurized Akkermansia muciniphila and Metabolic Health
A proof-of-concept randomized, double-blind, placebo-controlled trial in 32 overweight and obese insulin-resistant adults found that three months of supplementation with pasteurized Akkermansia muciniphila (10^10 cells/day) improved insulin sensitivity by 28.62% (P = 0.002), reduced insulinemia by 34.08% (P = 0.006), and decreased plasma total cholesterol by 8.68% (P = 0.02) compared to placebo.[5] Notably, the pasteurized (heat-killed) form showed slightly superior results compared to the live form, which showed only directionally favorable, non-significant trends. This finding is significant for the postbiotic category as a whole: it demonstrates that inactivation does not necessarily reduce efficacy and may, in some cases, enhance it. The authors attributed the effect to a thermostable outer membrane protein (Amuc_1100*) that retains its signaling activity after pasteurization.[5] For supplement formulators evaluating Akkermansia-based ingredients, the trial also established a clear dosing benchmark at 10^10 cells/day over a 3-month intervention period, with body weight and fat mass showing favorable but non-significant trends (P = 0.09) that suggest longer-duration studies may confirm additional endpoints.
Heat-Killed Lactobacillus Preparations and Gut Health
Heat-killed Lactobacillus helveticus CP790 improved stool consistency and reduced straining in a randomized, double-blind, placebo-controlled trial in healthy adults with constipation.[6] Heat-killed Lactobacillus acidophilus L-92 produced statistically significant improvement of nasal symptom-medication scores in a 49-patient, 8-week randomized, double-blind, placebo-controlled trial in perennial allergic rhinitis patients.[7]
IMMUSE LC-Plasma and Immune Activation
IMMUSE (heat-killed Lactococcus lactis strain Plasma, Kyowa Hakko) activates plasmacytoid dendritic cells (pDCs), which in turn stimulate natural killer (NK) cells, killer T-cells, helper T-cells, and B-cells. The ingredient is supported by 30 published studies, including 15 human clinical trials.[8]
OM-85 Bacterial Lysate and Respiratory Immunity
OM-85 (Broncho-Vaxom), an oral lyophilized bacterial lysate from eight common respiratory pathogens, has been studied in systematic reviews and meta-analyses. A 2025 systematic review found that OM-85 therapy led to approximately 9% higher proportion of patients remaining exacerbation-free compared to placebo in chronic airway disease populations.[9] Expert consensus from a 2022 Delphi study recognized OM-85 as the most studied immunomodulating bacterial lysate.[10]
Formulation Advantages: Stability, Shelf Life, and Dosage Form Compatibility
Postbiotic ingredients eliminate the central formulation challenge associated with probiotics: maintaining viable cell counts through manufacturing, storage, and gastrointestinal transit. This translates to measurable advantages across the supply chain.
Stability and Shelf Life
Postbiotic preparations are inherently stable because the microorganisms are already inanimate. There is no CFU decay over time, no requirement for refrigeration, and no sensitivity to moisture, oxygen, or gastric acidity.[2] Probiotics, by contrast, typically lose 10-15% of viable cells per month at ambient temperature, often requiring cold-chain logistics and refrigerated storage. For brands distributing supplements across hot climates, regions with inconsistent cold-chain infrastructure, or e-commerce channels where warehouse temperature control is variable, this stability difference directly affects product claims at the point of consumer use. Overage requirements that are standard practice for probiotic formulations (adding 20-50% excess CFU at manufacture to guarantee label claim at expiry) are not necessary for postbiotic ingredients, simplifying both cost modeling and regulatory label compliance.
Dosage Form Compatibility
Postbiotics are compatible with capsules, tablets, powders, sachets, gummies, beverages, functional foods, and baked goods. Heat-processed applications where live probiotics cannot survive, such as hot beverages, baked products, and pasteurized functional foods, are accessible to postbiotic ingredients.[2] Kerry’s Plenibiotic is formulated at 50-100 mg doses, demonstrating low-dose feasibility that simplifies tablet and capsule formulation compared to the high-CFU doses required for many probiotic strains. The compression forces involved in tableting, which are a known cause of viability loss in probiotic formulations, have no impact on inanimate postbiotic preparations. This opens up direct-compression tablet formats, effervescent tablets, and multi-layer tablet designs that are difficult or impossible to execute with live organisms. For functional food and beverage developers, postbiotics can withstand the pasteurization, retort, and ultra-high-temperature (UHT) processing steps that are standard in shelf-stable product manufacturing.
Table 1: Formulation Comparison of Postbiotics vs. Probiotics
| Parameter | Probiotics | Postbiotics |
|---|---|---|
| Viability requirement | Must maintain CFU count through shelf life | No viability requirement |
| Cold chain | Many strains require 2-8 C storage | Room-temperature stable |
| Typical shelf life | 6-24 months with significant CFU loss at ambient conditions | Extended shelf life at ambient; no viability decay |
| Moisture sensitivity | High; water activity affects survival | Low; inanimate cells unaffected |
| pH tolerance | Limited; many strains sensitive to acidic environments | Broad pH tolerance |
| Heat processing compatibility | Not compatible; cells destroyed | Fully compatible |
| Typical dose | Billions of CFU (often 1-100 billion) | Milligrams to grams of inactivated preparation |
| Tableting/compression | Challenging; compression forces reduce viability | Standard compression compatible |
When to Choose Postbiotics Over Probiotics
Postbiotics are not a universal replacement for probiotics. The two categories address different biological mechanisms and are best evaluated as complementary ingredient options depending on the formulation goal.
Table 2: Decision Guide for Supplement Formulators Evaluating Postbiotics vs. Probiotics
| Decision Factor | Probiotics Preferred | Postbiotics Preferred |
|---|---|---|
| Therapeutic goal | Live colonization, microbiome restructuring | Defined bioactive delivery, immune modulation |
| Patient population | Healthy adults (low risk) | Immunocompromised, neonates, critically ill (enhanced safety) |
| Dosage form | Refrigerated capsules, sachets | Heat-processed foods, ambient-stable tablets, gummies, beverages |
| Storage and distribution | Cold chain available | Ambient distribution required, hot climates |
| Manufacturing consistency | Acceptable CFU variability | High batch-to-batch reproducibility required |
| Clinical evidence depth | Extensive (decades for established strains) | Growing but limited for most ingredients |
| Shelf-life requirements | Shorter shelf life acceptable | Extended shelf life needed |
Safety Profile and Advantages Over Live Probiotics
Postbiotics offer a distinct safety advantage over live probiotics, particularly in populations where viable microorganism administration carries elevated risk. A comprehensive review by Pique et al. (2019) documented the safety profile of heat-killed (tyndallized) probiotic preparations, noting the elimination of key risk categories associated with live organisms.[4]
Risk Reduction in Vulnerable Populations
Live probiotics, while generally safe in healthy individuals, carry documented risks in immunocompromised patients, critically ill individuals, neonates, and oncology patients. These risks include bacteremia from translocation of live organisms across compromised gut barriers and horizontal transfer of antibiotic resistance genes to gut microbiota.[11] Postbiotic preparations eliminate these risks: inanimate cells cannot colonize, replicate, cause infection, or transfer genetic material.[4]
Regulatory Safety Precedent
The European Food Safety Authority (EFSA) assessed pasteurized Akkermansia muciniphila as a “well-characterised non-toxin producing, avirulent microorganism” and declared it safe at up to 3.4 x 10^10 cells/day in adults.[12] This assessment established a regulatory safety precedent for postbiotic ingredients in the EU.
Regulatory Status by Region
No major regulatory jurisdiction has established a dedicated framework specifically for postbiotics. Postbiotic ingredients are assessed under existing pathways for dietary supplements, novel foods, or natural health products depending on the region.
United States (FDA)
Postbiotic ingredients used in dietary supplements follow the New Dietary Ingredient (NDI) notification pathway under the Dietary Supplement Health and Education Act (DSHEA) if the ingredient was not marketed before October 15, 1994. HealthBiome received FDA NDI acknowledgment (NDIN #1363) in December 2024 for pasteurized Akkermansia muciniphila at 1.0 x 10^10 cells/day.[13] For food use, postbiotic preparations require a GRAS (Generally Recognized as Safe) determination. EpiCor (Cargill) has self-affirmed GRAS status for food applications.
European Union (EFSA / Novel Food)
Postbiotics lacking a history of significant consumption in the EU before May 15, 1997, require Novel Food authorization under Regulation (EU) 2015/2283. Pasteurized Akkermansia muciniphila was the first postbiotic to receive EU Novel Food authorization, approved via Commission Implementing Regulation (EU) 2022/168 following a positive EFSA safety opinion.[12] An extension of use opinion was adopted in 2025.[14]
Japan
Japan has the most mature postbiotic product landscape. The FOSHU (Foods for Specified Health Uses) pathway, established in 1991, and the FFC (Foods with Function Claims) pathway, established in 2015, both accommodate postbiotic preparations. Heat-killed lactic acid bacteria products have a documented history of safe consumption through traditional Japanese fermented foods.[15]
Other Regions
Health Canada has no postbiotic-specific guidance; heat-killed preparations do not fit the probiotic monograph (which requires “live”) and are assessed case-by-case under Natural Health Product regulations. Australia’s TGA accommodates non-viable microorganisms in listed medicines (AUST L) under complementary medicine pathways.
Supplier Landscape: Branded Postbiotic Ingredients
The postbiotic ingredient supply chain has matured considerably since the ISAPP definition was published in 2021, with several branded ingredients now available to supplement formulators.
Table 3: Branded Postbiotic Ingredients Available for Supplement Formulation
| Branded Ingredient | Supplier | Progenitor Organism | Primary Application | Key Feature |
|---|---|---|---|---|
| EpiCor | Cargill | Saccharomyces cerevisiae fermentate | Immune support, gut health | Self-affirmed GRAS; 10+ clinical studies |
| IMMUSE (LC-Plasma) | Kyowa Hakko | Lactococcus lactis strain Plasma | Immune support (pDC activation) | 30 published studies, 15 human trials |
| Plenibiotic | Kerry Group | Lactobacillus casei subsp. 327 | Gut health, skin health | 50-100 mg dose; vegan, non-GMO |
| LAC-Shield | Morinaga | Lacticaseibacillus paracasei MCC1849 | Immune support | Retains bioactivity after heat-killing |
| LAC-Living+ | Morinaga | Lactobacillus helveticus MCC1848 | Mental wellness, stress support | Proprietary strain |
| Humiome Post LB | dsm-firmenich | Two proprietary Lactobacillus strains + metabolites | Multi-area health | Combined strains + culture medium |
| Akkermansia MucT | A-Mansia Biotech | Akkermansia muciniphila MucT | Metabolic health, gut barrier | EU Novel Food authorized (2022) |
| HB05P | HealthBiome | Akkermansia muciniphila | Muscle health | FDA NDI acknowledged (Dec 2024) |
Quality, Analytical Methods, and Standardization
Quality assurance for postbiotic ingredients presents unique analytical challenges. Traditional probiotic quality metrics, such as CFU counts via plate culture, are not applicable because inanimate cells do not form colonies.[16]
Enumeration Methods
Flow cytometry (FCM) has emerged as the primary method for postbiotic cell enumeration. FCM uses fluorescent dyes such as propidium iodide to assess membrane integrity and quantify intact inanimate cells, with results expressed in Total Fluorescent Units (TFU). EFSA adopted FCM-based TFU enumeration for the authorized Akkermansia muciniphila preparation, establishing a regulatory precedent.[12,16] Quantitative polymerase chain reaction (qPCR) and digital PCR complement FCM by providing strain-level identification where DNA remains intact after inactivation. For procurement teams evaluating postbiotic ingredient suppliers, the practical implication is that certificates of analysis (COAs) should report cell counts in TFU or equivalent fluorescence-based units rather than CFU. A COA listing only CFU would indicate either a live probiotic product or an analytical method mismatch. Suppliers that provide FCM-based enumeration alongside qPCR strain confirmation and metabolite profiling represent the current quality benchmark for postbiotic ingredients.
Metabolite Characterization
Metabolomics approaches using gas chromatography-mass spectrometry (GC-MS) and high-performance liquid chromatography (HPLC) characterize the bioactive metabolite profiles of postbiotic preparations. Whole genome sequencing (WGS) screens for virulence factors and antimicrobial resistance genes. EFSA requires WGS-based safety screening even for non-viable preparations.[17]
Standardization Gap
No harmonized international standard for postbiotic enumeration or potency testing exists as of 2026. The absence of a single “gold standard” method creates challenges for quality assurance across manufacturers and complicates direct comparison between products.[16,17]
FAQs
What is the ISAPP definition of a postbiotic?
The International Scientific Association for Probiotics and Prebiotics (ISAPP) defines a postbiotic as “a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host.” The microorganism must be characterized to the strain level, and a health benefit must be demonstrated in a human study.[1]
Are postbiotics safer than probiotics?
Postbiotics eliminate certain safety risks associated with live probiotics, including bacteremia from bacterial translocation, horizontal transfer of antibiotic resistance genes, and colonization in vulnerable individuals. This makes postbiotics particularly relevant for immunocompromised, neonatal, and critically ill populations where live microorganism administration carries elevated risk.[4,11]
Do purified short-chain fatty acids (SCFAs) such as butyrate qualify as postbiotics?
No. The ISAPP definition explicitly excludes purified metabolites without cellular biomass. Isolated butyric acid, lactic acid, and other SCFAs sold as supplements are not postbiotics under the consensus definition. To qualify, a preparation must contain inanimate microbial cells or cell components.[1,3]
How are postbiotic ingredients quantified on a certificate of analysis?
Flow cytometry using fluorescent dyes is the primary enumeration method, with results expressed in Total Fluorescent Units (TFU). Traditional CFU plate counting is not applicable because inanimate cells do not form colonies. qPCR and digital PCR provide complementary strain-level identification.[16]
What regulatory pathway applies to postbiotic dietary supplements in the United States?
Postbiotic ingredients follow the New Dietary Ingredient (NDI) notification pathway under DSHEA if the ingredient was not marketed before October 15, 1994. For food use, a GRAS determination is required. No dedicated FDA regulatory category for postbiotics exists.[13]
Can postbiotics replace probiotics in supplement formulations?
Postbiotics are not a universal replacement for probiotics. They are complementary categories addressing different biological mechanisms. Where live colonization or long-term microbiome restructuring is the goal, probiotics may be more appropriate. Where stability, manufacturing consistency, and safety in vulnerable populations are priorities, postbiotics offer advantages.
Which postbiotic ingredient has the most extensive clinical evidence?
IMMUSE LC-Plasma (Kyowa Hakko) is supported by 30 published studies including 15 human clinical trials. EpiCor (Cargill) has over 10 clinical studies. Pasteurized Akkermansia muciniphila (A-Mansia Biotech) has the strongest evidence in the metabolic health space, with a landmark trial published in Nature Medicine.[5,8]
Key Takeaways
- Postbiotics are preparations of inanimate microorganisms and/or their components that confer a health benefit, as defined by the 2021 ISAPP consensus; the term excludes purified metabolites, vaccines, and products from uncharacterized cultures.
- Postbiotic ingredients offer superior shelf stability, room-temperature storage, broad dosage form compatibility (including heat-processed applications), and a favorable safety profile compared to live probiotics.
- Pasteurized Akkermansia muciniphila improved insulin sensitivity by 28.62% in a randomized, placebo-controlled trial, with the pasteurized form outperforming the live form.[5]
- No major regulatory jurisdiction has a dedicated postbiotic framework; ingredients are assessed under existing dietary supplement (FDA NDI/DSHEA), novel food (EU), or natural health product pathways.
- Eight branded postbiotic ingredients are commercially available from suppliers including Cargill (EpiCor), Kyowa Hakko (IMMUSE), Kerry Group (Plenibiotic), Morinaga (LAC-Shield), and A-Mansia Biotech (Akkermansia MucT).
- Flow cytometry (Total Fluorescent Units) is the primary analytical method for postbiotic enumeration; traditional CFU plate counting is not applicable to inanimate preparations.
- Clinical evidence for most postbiotic ingredients remains limited to small, short-term trials; dose-response relationships and long-term safety data are still under development.
Sources
- Salminen S, Collado MC, Endo A, Hill C, Lebeer S, Quigley EMM, Sanders ME, Shamir R, Swann JR, Szajewska H, Vinderola G. “The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics.” Nature Reviews Gastroenterology & Hepatology, 2021; 18(9): 649-667. https://doi.org/10.1038/s41575-021-00440-6 (accessed May 2026).
- Vinderola G, Sanders ME, Salminen S, Szajewska H. “Postbiotics: The concept and their use in healthy populations.” Frontiers in Nutrition, 2022; 9: 1002213. https://doi.org/10.3389/fnut.2022.1002213 (accessed May 2026).
- Vinderola G, Sanders ME, Cunningham M, Hill C. “Frequently asked questions about the ISAPP postbiotic definition.” Frontiers in Microbiology, 2023; 14: 1324565. https://doi.org/10.3389/fmicb.2023.1324565 (accessed May 2026).
- Pique N, Berlanga M, Minana-Galbis D. “Health Benefits of Heat-Killed (Tyndallized) Probiotics: An Overview.” International Journal of Molecular Sciences, 2019; 20(10): 2534. https://doi.org/10.3390/ijms20102534 (accessed May 2026).
- Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM, de Barsy M, Loumaye A, Hermans MP, Thissen JP, de Vos WM, Cani PD. “Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study.” Nature Medicine, 2019; 25(7): 1096-1103. https://doi.org/10.1038/s41591-019-0495-2 (accessed May 2026).
- “Effects of Heat-Treated Lactobacillus helveticus CP790-Fermented Milk on Gastrointestinal Health in Healthy Adults: A Randomized Double-Blind Placebo-Controlled Trial.” Nutrients, 2024; 16(14): 2191. https://www.mdpi.com/2072-6643/16/14/2191 (accessed May 2026).
- Ishida Y et al. “Clinical Effects of Lactobacillus acidophilus Strain L-92 on Perennial Allergic Rhinitis: A Double-Blind, Placebo-Controlled Study.” Journal of Dairy Science, 2005; 88(2): 527-533. https://pubmed.ncbi.nlm.nih.gov/15653517/ (accessed May 2026).
- Kyowa Hakko, “IMMUSE LC-Plasma Postbiotic.” https://immusehealth.com/what-is-immuse-postbiotic (accessed May 2026).
- Lee J. “Efficacy of OM-85 (Broncho-Vaxom) for prevention of acute exacerbations in patients with chronic airway diseases or chronic bronchitis: a systematic review and meta-analysis.” Journal of Thoracic Disease, 2025. https://doi.org/10.21037/jtd-2025-1166 (accessed May 2026).
- “Expert consensus on the role of OM-85 in the management of recurrent respiratory infections: A Delphi study.” Human Vaccines & Immunotherapeutics, 2022. https://doi.org/10.1080/21645515.2022.2106720 (accessed May 2026).
- Merenstein D, Pot B, Leyer G, Ouwehand AC, Preidis GA, Elkins CA, Hill C, Lewis ZT, Shane AL, Zmora N, Petrova MI, Collado MC, Morelli L, Montoya GA, Szajewska H, Tancredi DJ, Sanders ME. “Emerging issues in probiotic safety: 2023 perspectives.” Gut Microbes, 2023; 15(1): 2185034. https://doi.org/10.1080/19490976.2023.2185034 (accessed May 2026).
- EFSA NDA Panel. “Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283.” EFSA Journal, 2021; 19(9): 6780. https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2021.6780 (accessed May 2026).
- U.S. Food & Drug Administration. “New Dietary Ingredient (NDI) Notification Process.” https://www.fda.gov/food/dietary-supplements/new-dietary-ingredient-ndi-notification-process (accessed May 2026).
- EFSA NDA Panel. “Safety of an extension of use of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283.” EFSA Journal, 2025; 9632. https://efsa.onlinelibrary.wiley.com/doi/full/10.2903/j.efsa.2025.9632 (accessed May 2026).
- ISAPP. “Postbiotics and probiotics in Japan: A researcher’s perspective.” https://isappscience.org/resource/episode-12-postbiotics-and-probiotics-in-japan-a-researchers-perspective/ (accessed May 2026).
- Boyte ME, Benkowski A, Pane M, Shehata HR. “Probiotic and postbiotic analytical methods: a perspective of available enumeration techniques.” Frontiers in Microbiology, 2023; 14: 1304621. https://doi.org/10.3389/fmicb.2023.1304621 (accessed May 2026).
- Vinderola G et al. “Postbiotics: a perspective on their quantification.” Frontiers in Nutrition, 2025; 12: 1582733. https://doi.org/10.3389/fnut.2025.1582733 (accessed May 2026).
These statements have not been evaluated by the Food and Drug Administration. This information is provided for dietary supplement industry professionals and is not intended to diagnose, treat, cure, or prevent any disease.
Read our Introduction to Probiotics and Prebiotics in Nutraceuticals
